OR-GUROBI-OPTIMIZATION
1.9.2022 16:51:42 CEST | Business Wire | Press release
Gurobi Optimization, LLC, creator of the world’s fastest mathematical optimization solver, has launched a new program to help independent software vendors (ISVs) tackle customers’ increasingly complex business challenges and keep up with ever-evolving customer needs.
While 85% of Fortune 500 companies use mathematical optimization, smaller startups and scaleups in the tech world are catching on to the value an industry-leading solver like Gurobi can bring to their software solutions. In fact, 70% of top global tech companies now use Gurobi.
Gurobi wants to be more than just a supplier to the ISVs that utilize its mathematical optimization technology; it wants to be a partner. That is the motivation behind the new Gurobi Partner Accelerator Program.
The 36-month program aims to create joint value between Gurobi and solution providers by setting and achieving shared business, product, and revenue goals.
“It’s not just a supplier relationship. We see it as a partnership. We want to support these companies and go hand-in-hand with them. If they grow, we grow together,” explained Jan Schwarzkopf, Gurobi Account Manager - Europe Ecosystem.
The Gurobi Partner Accelerator Program
Gurobi is offering a partnership with companies in the final stages of developing a software solution that utilizes its optimization technology. Companies will receive ongoing technical support, which is a critical asset in these final development stages.
In addition to technical support, partner companies will receive business and marketing support to accelerate their product’s time to market and maximize sales once launched.
This program is not just for companies in the development stage, though. ISVs that utilize Gurobi for products already on the market will also be eligible. The program’s ongoing technical and business support is essential for any company that wants to enhance its product to stay ahead in the highly competitive software market.
Benefits of the Program
By participating in the program, ISVs will receive the following:
- Easy Access to Gurobi’s Technology - Solution partners will receive access to Gurobi’s best-in-class technology, including a product license based on their business needs.
- Ongoing Sales and Marketing Support - The program includes guidance on sales and marketing strategies. Gurobi will work hand-in-hand with partners to advise on the best way to market their product and maximize sales once launched.
- Quarterly Engagement for Business Strategy - Gurobi will meet at least quarterly with solution partners to assist with high-level business strategy. Partners will get expert guidance on formulating and executing business goals.
Who Should Consider This Program?
The Gurobi Partner Accelerator Program is not limited to ISVs currently using Gurobi’s technology for their software solutions. Companies using an open-source solver or competitive commercial solver are also encouraged to consider the program.
For those using either an open-source or commercial solver, Gurobi poses the following questions:
- Are you or your end customers satisfied with the current performance of your software application?
- Does your relationship with your current optimization technology supplier support your business growth?
If the answer to one or both of these questions is no, the Gurobi Partner Accelerator Program might be the solution.
The software industry is getting more competitive every year, and ISVs need to ensure their solutions use every advantage available. The Gurobi Partner Accelerator Program is an excellent opportunity to access leading optimization solver technology, as well as hands-on support from experts who want their partners to succeed with optimization.
To learn more about the program, please visit https://www.gurobi.com/gurobi-alliance/gurobi-partner-accelerator-program/.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98.5% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
